Effect of indinavir used alone or in double or triple combination with AZT and ddC on human immune functions.
Indinavir (IDV) is a potent and selective human immunodeficiency virus type 1 (HIV-1) protease inhibitor (PI) widely used in antiretroviral therapy, but its effects on the immune system are relatively unknown. In this study we have investigated the in vitro effect of IDV on normal human peripheral blood mononuclear cells (PBMC). We used the drug alone or in double and triple combination with AZT and ddC to assess whether IDV interferes with the previously observed immunomodulatory effects induced by AZT and ddC. We found that proliferative response, induction of immunoglobulins (Ig) production and cytokine production was not modulated by IDV. More importantly, IDV used in double or triple combination with AZT and ddC, does not further strenghten the inhibition of proliferative response induced by AZT and is able to abrogate the inhibitory effect induced by ddC on proliferative response. Similarly, IDV/AZT, IDV/ddC and IDV/AZT/ddC combinations does not strenghten the modulation of TNF-alpha, IFN-gamma and IL-4 induced by AZT, ddC and AZT/ddC. On the other hand, IDV neutralizes the up-regulating effects of AZT on IL-2 production while the up-regulating effects of ddC on IL-2 production is not affected. These data suggest that IDV used in combination with AZT and ddC did not add any further immunotoxicity.
Department of Immunology Istituto Superiore di Sanità, Viale Regina Elena 299, 00161, Rome, Italy.
Benedetta
B
Mattioli
Luciana
L
Giordani
Maria Giovanna
MG
Quaranta
Marina
M
Viora
D000276:Adjuvants, Immunologic / Q000494:pharmacology*; D019380:Anti-HIV Agents / Q000494:pharmacology; D002455:Cell Division / Q000187:drug effects; D016207:Cytokines / Q000096:biosynthesis; D004347:Drug Interactions; D017320:HIV Protease Inhibitors / Q000494:pharmacology*; D006801:Humans; D007136:Immunoglobulins / Q000096:biosynthesis; D019469:Indinavir / Q000494:pharmacology*; D007963:Leukocytes, Mononuclear / Q000187:drug effects / Q000276:immunology; D008213:Lymphocyte Activation; D016047:Zalcitabine / Q000494:pharmacology; D015215:Zidovudine / Q000494:pharmacology
D000276:Adjuvants, Immunologic; D019380:Anti-HIV Agents; D016207:Cytokines; D017320:HIV Protease Inhibitors; D007136:Immunoglobulins; D015215:Zidovudine; D019469:Indinavir; D016047:Zalcitabine